VEGF-D Promotes Tumor Metastasis by Regulating Prostaglandins Produced by the Collecting Lymphatic Endothelium

Cancer Cell

Volumn 21, Issue 2, 2012, Pages 181-195

  Karnezis, Tara ^a,b,d   Shayan, Ramin ^a,b,d   Caesar, Carol ^a,b,d   Roufail, Sally ^a,b,d   Harris, Nicole C ^a,b,d   Ardipradja, Kathryn ^a,b,d   Zhang, YouFang ^a,b,d   Williams, Steven P ^a,b,d   Farnsworth, Rae H ^a,b,d   Chai, Ming G ^e   Rupasinghe, Thusitha W T ^c   Tull, Dedreia L ^c   Baldwin, Megan E ^f   Sloan, Erica K ^e   Fox, Stephen B ^a,b   Achen, Marc G ^a,b,d   Stacker, Steven A ^a,b,d  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d ROYAL MELBOURNE HOSPITAL   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f Vegenics Pty Ltd   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; NONSTEROID ANTIINFLAMMATORY AGENT; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 2; VASCULOTROPIN RECEPTOR 3;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; ENDOTHELIUM CELL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LYMPH VESSEL ENDOTHELIUM; LYMPHANGIOGENESIS; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; VASODILATATION;

EID: 84863011445     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccr.2011.12.026     Document Type: Article

References (70)

1. Achen M.G., Stacker S.A. Tumor lymphangiogenesis and metastatic spread-new players begin to emerge. Int. J. Cancer 2006, 119:1755-1760.
2. Achen M.G., Stacker S.A. Molecular control of lymphatic metastasis. Ann. N Y Acad. Sci. 2008, 1131:225-234.
3. Achen M.G., Jeltsch M., Kukk E., Mäkinen T., Vitali A., Wilks A.F., Alitalo K., Stacker S.A. Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc. Natl. Acad. Sci. USA 1998, 95:548-553.
4. Achen M.G., Roufail S., Domagala T., Catimel B., Nice E.C., Geleick D.M., Murphy R., Scott A.M., Caesar C., Makinen T., et al. Monoclonal antibodies to vascular endothelial growth factor-D block its interactions with both VEGF receptor-2 and VEGF receptor-3. Eur. J. Biochem. 2000, 267:2505-2515.
5. Albuquerque R.J., Hayashi T., Cho W.G., Kleinman M.E., Dridi S., Takeda A., Baffi J.Z., Yamada K., Kaneko H., Green M.G., et al. Alternatively spliced vascular endothelial growth factor receptor-2 is an essential endogenous inhibitor of lymphatic vessel growth. Nat. Med. 2009, 15:1023-1030.
6. Amano H., Hayashi I., Endo H., Kitasato H., Yamashina S., Maruyama T., Kobayashi M., Satoh K., Narita M., Sugimoto Y., et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. J.Exp. Med. 2003, 197:221-232.
7. Backlund M.G., Mann J.R., Dubois R.N. Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology 2005, 69(Suppl 1):28-32.
8. Backlund M.G., Mann J.R., Holla V.R., Buchanan F.G., Tai H.H., Musiek E.S., Milne G.L., Katkuri S., DuBois R.N. 15-Hydroxyprostaglandin dehydrogenase is down-regulated in colorectal cancer. J.Biol. Chem. 2005, 280:3217-3223.
9. Baluk P., Fuxe J., Hashizume H., Romano T., Lashnits E., Butz S., Vestweber D., Corada M., Molendini C., Dejana E., McDonald D.M. Functionally specialized junctions between endothelial cells of lymphatic vessels. J.Exp. Med. 2007, 204:2349-2362.
10. Björndahl M.A., Cao R., Burton J.B., Brakenhielm E., Religa P., Galter D., Wu L., Cao Y. Vascular endothelial growth factor-a promotes peritumoral lymphangiogenesis and lymphatic metastasis. Cancer Res. 2005, 65:9261-9268.
11. Cao R., Björndahl M.A., Religa P., Clasper S., Garvin S., Galter D., Meister B., Ikomi F., Tritsaris K., Dissing S., et al. PDGF-BB induces intratumoral lymphangiogenesis and promotes lymphatic metastasis. Cancer Cell 2004, 6:333-345.
12. Cha Y.I., DuBois R.N. NSAIDs and cancer prevention: targets downstream of COX-2. Annu. Rev. Med. 2007, 58:239-252.
13. Challis J.R., Dilley S.R., Robinson J.S., Thorburn G.D. Prostaglandins in the circulation of the fetal lamb. Prostaglandins 1976, 11:1041-1052.
14. Clasper S., Royston D., Baban D., Cao Y., Ewers S., Butz S., Vestweber D., Jackson D.G. A novel gene expression profile in lymphatics associated with tumor growth and nodal metastasis. Cancer Res. 2008, 68:7293-7303.
15. Coggins K.G., Latour A., Nguyen M.S., Audoly L., Coffman T.M., Koller B.H. Metabolism of PGE2 by prostaglandin dehydrogenase is essential for remodeling the ductus arteriosus. Nat. Med. 2002, 8:91-92.
16. Di J.M., Zhou J., Zhou X.L., Gao X., Shao C.Q., Pang J., Sun Q.P., Zhang Y., Ruan X.X. Cyclooxygenase-2 expression is associated with vascular endothelial growth factor-C and lymph node metastases in human prostate cancer. Arch. Med. Res. 2009, 40:268-275.
17. Farnsworth R.H., Karnezis T., Shayan R., Matsumoto M., Nowell C.J., Achen M.G., Stacker S.A. A role for bone morphogenetic protein-4 in lymph node vascular remodeling and primary tumor growth. Cancer Res. 2011, 71:6547-6557.
18. Fukumura D., Kashiwagi S., Jain R.K. The role of nitric oxide in tumour progression. Nat. Rev. Cancer 2006, 6:521-534.
19. Glaser K., Sung M.L., O'Neill K., Belfast M., Hartman D., Carlson R., Kreft A., Kubrak D., Hsiao C.L., Weichman B. Etodolac selectively inhibits human prostaglandin G/H synthase 2 (PGHS-2) versus human PGHS-1. Eur. J. Pharmacol. 1995, 281:107-111.
20. Greenhough A., Smartt H.J., Moore A.E., Roberts H.R., Williams A.C., Paraskeva C., Kaidi A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis 2009, 30:377-386.
21. Gupta R.A., Dubois R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 2001, 1:11-21.
22. Hansen-Petrik M.B., McEntee M.F., Jull B., Shi H., Zemel M.B., Whelan J. Prostaglandin E(2) protects intestinal tumors from nonsteroidal anti-inflammatory drug-induced regression in Apc(Min/+) mice. Cancer Res. 2002, 62:403-408.
23. He Y., Rajantie I., Pajusola K., Jeltsch M., Holopainen T., Yla-Herttuala S., Harding T., Jooss K., Takahashi T., Alitalo K. Vascular endothelial cell growth factor receptor 3-mediated activation of lymphatic endothelium is crucial for tumor cell entry and spread via lymphatic vessels. Cancer Res. 2005, 65:4739-4746.
24. Hirsch H.A., Iliopoulos D., Joshi A., Zhang Y., Jaeger S.A., Bulyk M., Tsichlis P.N., Shirley Liu X., Struhl K. A transcriptional signature and common gene networks link cancer with lipid metabolism and diverse human diseases. Cancer Cell 2010, 17:348-361.
25. Holmes M.D., Chen W.Y., Li L., Hertzmark E., Spiegelman D., Hankinson S.E. Aspirin intake and survival after breast cancer. J.Clin. Oncol. 2010, 28:1467-1472.
26. Hoshida T., Isaka N., Hagendoorn J., di Tomaso E., Chen Y.L., Pytowski B., Fukumura D., Padera T.P., Jain R.K. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res. 2006, 66:8065-8075.
27. Iwata C., Kano M.R., Komuro A., Oka M., Kiyono K., Johansson E., Morishita Y., Yashiro M., Hirakawa K., Kaminishi M., Miyazono K. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Res. 2007, 67:10181-10189.
28. Jaffe B.M., Parker C.W., Philpott G.W. Immunochemical measurement of prostaglandin or prostaglandin-like activity from normal and neoplastic cultured tissue. Surg. Forum 1971, 22:90-92.
29. Jeltsch M., Kaipainen A., Joukov V., Meng X., Lakso M., Rauvala H., Swartz M., Fukumura D., Jain R.K., Alitalo K. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997, 276:1423-1425.
30. Joukov V., Pajusola K., Kaipainen A., Chilov D., Lahtinen I., Kukk E., Saksela O., Kalkkinen N., Alitalo K. A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J. 1996, 15:290-298.
31. Kerjaschki D., Bago-Horvath Z., Rudas M., Sexl V., Schneckenleithner C., Wolbank S., Bartel G., Krieger S., Kalt R., Hantusch B., et al. Lipoxygenase mediates invasion of intrametastatic lymphatic vessels and propagates lymph node metastasis of human mammary carcinoma xenografts in mouse. J.Clin. Invest. 2011, 121:2000-2012.
32. Kopfstein L., Veikkola T., Djonov V.G., Baeriswyl V., Schomber T., Strittmatter K., Stacker S.A., Achen M.G., Alitalo K., Christofori G. Distinct roles of vascular endothelial growth factor-D in lymphangiogenesis and metastasis. Am. J. Pathol. 2007, 170:1348-1361.
33. Koukourakis M.I., Giatromanolaki A., Thorpe P.E., Brekken R.A., Sivridis E., Kakolyris S., Georgoulias V., Gatter K.C., Harris A.L. Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer. Cancer Res. 2000, 60:3088-3095.
34. Kriehuber E., Breiteneder-Geleff S., Groeger M., Soleiman A., Schoppmann S.F., Stingl G., Kerjaschki D., Maurer D. Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages. J.Exp. Med. 2001, 194:797-808.
35. Kubo H., Hosono K., Suzuki T., Ogawa Y., Kato H., Kamata H., Ito Y., Amano H., Kato T., Sakagami H., et al. Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis. Biomed. Pharmacother. 2010, 64:101-106.
36. Leitzmann M.F., Stampfer M.J., Ma J., Chan J.M., Colditz G.A., Willett W.C., Giovannucci E. Aspirin use in relation to risk of prostate cancer. Cancer Epidemiol. Biomarkers Prev. 2002, 11:1108-1111.
37. Liu H., Yang Y., Xiao J., Lv Y., Liu Y., Yang H., Zhao L. COX-2-mediated regulation of VEGF-C in association with lymphangiogenesis and lymph node metastasis in lung cancer. Anat. Rec. (Hoboken) 2010, 293:1838-1846.
38. Liotta L.A. Cancer cell invasion and metastasis. Sci. Am. 1992, 266:54-59. 62-63.
39. Mäkinen T., Jussila L., Veikkola T., Karpanen T., Kettunen M.I., Pulkkanen K.J., Kauppinen R., Jackson D.G., Kubo H., Nishikawa S., et al. Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3. Nat. Med. 2001, 7:199-205.
40. Mäkinen T., Adams R.H., Bailey J., Lu Q., Ziemiecki A., Alitalo K., Klein R., Wilkinson G.A. PDZ interaction site in ephrinB2 is required for the remodeling of lymphatic vasculature. Genes Dev. 2005, 19:397-410.
41. Mandriota S.J., Jussila L., Jeltsch M., Compagni A., Baetens D., Prevo R., Banerji S., Huarte J., Montesano R., Jackson D.G., et al. Vascular endothelial growth factor-C-mediated lymphangiogenesis promotes tumour metastasis. EMBO J. 2001, 20:672-682.
42. Mantovani A., Allavena P., Sica A., Balkwill F. Cancer-related inflammation. Nature 2008, 454:436-444.
43. Messina E.J., Weiner R., Kaley G. Microcirculatory effects of prostaglandins E1, E2, and A1 in the rat mesentery and cremaster muscle. Microvasc. Res. 1974, 8:77-89.
44. Myung S.J., Rerko R.M., Yan M., Platzer P., Guda K., Dotson A., Lawrence E., Dannenberg A.J., Lovgren A.K., Luo G., et al. 15-Hydroxyprostaglandin dehydrogenase is an invivo suppressor of colon tumorigenesis. Proc. Natl. Acad. Sci. USA 2006, 103:12098-12102.
45. Nilsson I., Bahram F., Li X., Gualandi L., Koch S., Jarvius M., Söderberg O., Anisimov A., Kholová I., Pytowski B., et al. VEGF receptor 2/-3 heterodimers detected insitu by proximity ligation on angiogenic sprouts. EMBO J. 2010, 29:1377-1388.
46. Oliver G., Alitalo K. The lymphatic vasculature: recent progress and paradigms. Annu. Rev. Cell Dev. Biol. 2005, 21:457-483.
47. Olsson A.G., Carlson L.A. Clinical, hemodynamic and metabolic effects of intraarterial infusions of prostaglandin E1 in patients with peripheral vascular disease. Adv. Prostaglandin Thromboxane Res. 1976, 1:429-432.
48. Pepper M.S. Lymphangiogenesis and tumor metastasis: myth or reality?. Clin. Cancer Res. 2001, 7:462-468.
49. Pichaud F., Roux S., Frendo J.L., Delage-Mourroux R., Maclouf J., de Vernejoul M.C., Moukhtar M.S., Jullienne A. 1,25-dihydroxyvitamin D3 induces NAD(+)-dependent 15-hydroxyprostaglandin dehydrogenase in human neonatal monocytes. Blood 1997, 89:2105-2112.
50. Podgrabinska S., Braun P., Velasco P., Kloos B., Pepper M.S., Skobe M. Molecular characterization of lymphatic endothelial cells. Proc. Natl. Acad. Sci. USA 2002, 99:16069-16074.
51. Pugh S., Thomas G.A. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut 1994, 35:675-678.
52. Rigas B., Goldman I.S., Levine L. Altered eicosanoid levels in human colon cancer. J.Lab. Clin. Med. 1993, 122:518-523.
53. Ristimäki A., Honkanen N., Jänkälä H., Sipponen P., Härkönen M. Expression of cyclooxygenase-2 in human gastric carcinoma. Cancer Res. 1997, 57:1276-1280.
54. Roberts N., Kloos B., Cassella M., Podgrabinska S., Persaud K., Wu Y., Pytowski B., Skobe M. Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2. Cancer Res. 2006, 66:2650-2657.
55. Sappy P.C. Anatomy, Physiology and Pathology of Lymphatic Vessels in Man and Vertebrates 1874, DeLahaye, A, Paris.
56. Shayan R., Achen M.G., Stacker S.A. Lymphatic vessels in cancer metastasis: bridging the gaps. Carcinogenesis 2006, 27:1729-1738.
57. Skobe M., Hawighorst T., Jackson D.G., Prevo R., Janes L., Velasco P., Riccardi L., Alitalo K., Claffey K., Detmar M. Induction of tumor lymphangiogenesis by VEGF-C promotes breast cancer metastasis. Nat. Med. 2001, 7:192-198.
58. Sleeman J.P., Thiele W. Tumor metastasis and the lymphatic vasculature. Int. J. Cancer 2009, 125:2747-2756.
59. Sleeman J.P., Nazarenko I., Thiele W. Do all roads lead to Rome? Routes to metastasis development. Int. J. Cancer 2011, 128:2511-2526.
60. Sloan E.K., Priceman S.J., Cox B.F., Yu S., Pimentel M.A., Tangkanangnukul V., Arevalo J.M., Morizono K., Karanikolas B.D., Wu L., et al. The sympathetic nervous system induces a metastatic switch in primary breast cancer. Cancer Res. 2010, 70:7042-7052.
61. St Croix B., Rago C., Velculescu V., Traverso G., Romans K.E., Montgomery E., Lal A., Riggins G.J., Lengauer C., Vogelstein B., Kinzler K.W. Genes expressed in human tumor endothelium. Science 2000, 289:1197-1202.
62. Stacker S.A., Caesar C., Baldwin M.E., Thornton G.E., Williams R.A., Prevo R., Jackson D.G., Nishikawa S., Kubo H., Achen M.G. VEGF-D promotes the metastatic spread of tumor cells via the lymphatics. Nat. Med. 2001, 7:186-191.
63. Stacker S.A., Williams R.A., Achen M.G. Lymphangiogenic growth factors as markers of tumor metastasis. APMIS 2004, 112:539-549.
64. Tang E.H., Vanhoutte P.M. Gene expression changes of prostanoid synthases in endothelial cells and prostanoid receptors in vascular smooth muscle cells caused by aging and hypertension. Physiol. Genomics 2008, 32:409-418.
65. Tammela T., Alitalo K. Lymphangiogenesis: molecular mechanisms and future promise. Cell 2010, 140:460-476.
66. Thun M.J., Heath C.W. Aspirin use and reduced risk of gastrointestinal tract cancers in the American Cancer Society prospective studies. Prev. Med. 1995, 24:116-118.
67. Tsujii M., Kawano S., Tsuji S., Sawaoka H., Hori M., DuBois R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93:705-716.
68. Whorton A.R., Smigel M., Oates J.A., Frölich J.C. Regional differences in prostacyclin formation by the kidney. Prostacyclin is a major prostaglandin of renal cortex. Biochim. Biophys. Acta 1978, 529:176-180.
69. Williams C.S., Tsujii M., Reese J., Dey S.K., DuBois R.N. Host cyclooxygenase-2 modulates carcinoma growth. J.Clin. Invest. 2000, 105:1589-1594.
70. Wolf I., O'Kelly J., Rubinek T., Tong M., Nguyen A., Lin B.T., Tai H.H., Karlan B.Y., Koeffler H.P. 15-Hydroxyprostaglandin dehydrogenase is a tumor suppressor of human breast cancer. Cancer Res. 2006, 66:7818-7823.